China Survey of Peptic Ulcer Bleeding
Launched by ASTRAZENECA · Nov 12, 2010
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Female and/or male aged 18 years and above
- • Admitted to the hospital with an overt upper GI bleeding (hematemesis/coffee ground vomiting, melena, hematochezia and other clinical or laboratory evidence of acute blood loss from the upper GI tract)
- • Endoscopy demonstrated peptic ulcer bleeding (Forrest I-III)
- Exclusion Criteria:
- • If participating in any clinical trial, the subject cannot take part in this study.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fuzhou, Fujian, China
Guangzhou, Guangdong, China
Wuhan, Hubei, China
Nanjing, Jiangsu, China
Shenyang, Liaoning, China
Chengdu, Sichuan, China
Beijing, Beijing, China
Shanghai, Shanghai, China
Hangzhou, Zhejiang, China
Jinan, Shandong, China
Kunming, Yunnan, China
Shenzhen, Guangdong, China
Taiyuan, Shanxi, China
Wenzhou, Zhejiang, China
Changchun, Jilin, China
Xian, Shanxi, China
Hefei, Anhui, China
Chongqing, Chongqing, China
Xiamen, Fujian, China
Changsha, Hunan, China
Nanchang, Jiangxi, China
Tianjin, Tianjin, China
Nantong, Jiangsu, China
Lanzhou, Gansu, China
Haerbin, Heilongjiang, China
Jiangyin, Jiangsu, China
Huhehaote, Neimeng, China
Yangquan, Shanxi, China
Wulumuqi, Xinjiang, China
Fuyang, Zhejiang, China
Jinhua, Zhejiang, China
Patients applied
Trial Officials
Karen Atkin
Study Director
Astrazeneca China R&D
Zhaoshen Li
Principal Investigator
Changhai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials